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Background: 
High failure rates of metal-on-metal (MoM) hip implants prompted regulatory authorities to 
issue worldwide safety alerts. Circulating cobalt from these implants causes rare but fatal 
autopsy-diagnosed cardiotoxicity. There is concern that milder cardiotoxicity may be 
common and underrecognized. Although blood metal ion levels are easily measured and 
can be used to track local toxicity, there are no noninvasive tests for organ deposition. We 
sought to detect and constrain correlation between blood metal ions and a comprehensive 
panel of established markers of early cardiotoxicity. 
Methods: 
Ninety patients were recruited into this prospective single-center blinded study. Patients 
were divided into 3 age and sex-matched groups according to implant type and whole-blood 
metal ion levels. Group-A patients had a ceramic-on-ceramic [CoC] bearing; Group B, an 
MoM bearing and low blood metal ion levels; and Group C, an MoM bearing and high blood 
metal-ion levels. All patients underwent detailed cardiovascular phenotyping using cardiac 
magnetic resonance imaging (CMR) with T2*, T1, and extracellular volume mapping; 
echocardiography; and cardiac blood biomarker sampling. T2* is a novel CMR biomarker of 
tissue metal loading. Primary outcomes were prespecified on trial registration 
(ClinicalTrials.gov: NCT02331264). 
Results: 
Blood cobalt levels differed significantly among groups A, B, and C (mean and standard 
deviation [SD], 0.17 ± 0.08, 2.47 ± 1.81, and 30.0 ± 29.1 ppb, respectively) and between 
group A and groups B and C combined. No significant between-group differences were 
found in the left atrial or ventricle size, ejection fraction (on CMR or echocardiography), T1 or 
T2* values, extracellular volume, B-type natriuretic peptide level, or troponin level, and all 
values were within normal ranges. There was no relationship between cobalt levels and 
ejection fraction (R = 0.022, 95% confidence interval [CI] = −0.185 to 0.229) or T2* values (R 
= −0.108, 95% CI = −0.105 to 0.312). 
Conclusions: 
Using the best available technologies, we did not find that high (but not extreme) blood 
cobalt and chromium levels had any significant cardiotoxic effect on patients with an MoM 
hip implant. There were negligible-to-weak correlations between elevated blood metal ion 
levels and ejection fraction even at the extremes of the 95% CI, which excludes any clinically 
important association. 
Level of Evidence: 
Therapeutic Level II. See Instructions for Authors for a complete description of levels of 
evidence. 
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Over one million patients worldwide have implanted metal-on-metal (MoM) hip 
prostheses, predominantly composed of cobalt-chromium alloy1. Release of nano-particulate 
debris and metal ions from implants has been reported to cause harm2. Local soft-tissue 
deposition adjacent to the joint3-5 results in high failure rates of MoM hip implants. This led 
regulatory agencies to issue safety alerts against their use6-8, necessitating surveillance that 
includes serial measurement of blood metal ion levels and cross-sectional imaging to guide 
revision surgery9. 
The relationship between MoM hip implants and systemic toxicity is less clear. 
Elevated levels of circulating cobalt have been linked with cardiac, thyroid, and neuro-ocular 
abnormalities in case reports, but causation and prevalence remain to be established10-18. 
Diagnosis of cardiotoxicity requires invasive myocardial biopsy or postmortem examination, 
with no available noninvasive methods for measuring metal deposition. Heart failure is 
common in the patient population most likely to undergo hip replacement19, so there is 
concern that an association between MoM hip prostheses and heart failure may be missed. 
One echocardiography study showed a 7% reduction in left ventricular ejection fraction in 
MoM-implant recipients20 (although all values were within the normal range). More recently, 
an epidemiological study that compared 121 subjects who had 1 type of MoM hip prosthesis 
with 3,546 subjects who had a metal-on-plastic (MoP) prosthesis showed the age-adjusted 
rate of hospitalization for heart failure to be equivalent to 1 such hospitalization for every 11 
patients21. The Therapeutic Goods Administration (Australian Department of Health) 
consequently published a safety alert pending further investigation22. 
Cardiac magnetic resonance imaging (CMR) is the gold-standard technique for 
measuring cardiac volumes and function. In addition, the CMR T2* method for assessing 
cardiac iron has been histologically validated and has become a routine measure, 
transforming the management of patients at risk for iron cardiomyopathy23,24. As cobalt 
exhibits a magnetic property similar to that of iron, T2* mapping has the potential to 
noninvasively detect tissue deposition of cobalt in patients with a failing MoM hip prosthesis, 
as recently demonstrated by our group25. 
The present study of patients with an MoM hip prosthesis was designed to assess the 
effect of elevated whole-blood metal ion levels on cardiac function as well as to seek 
evidence of cardiac metal ion deposition with gold-standard multimodality imaging and 
measurement of serum biomarkers to minimize potential bias. 
Materials and Methods 
Study Design 
In this single-center blinded cross-sectional study, all patients underwent CMR, 
transthoracic echocardiography, and blood sampling during a single visit (Fig. 1). The 
research was approved by the institutional review board and ethics committee (reference: 
14/LO/1722) and was registered in ClinicalTrials.gov (NCT02331264). 
Setting 
Between October 2014 and November 2015, 108 patients were recruited from 
specialist outpatient clinics held at the Royal National Orthopaedic Hospital and cardiac 
assessment was performed at the Heart Hospital (both University College London hospitals, 
U.K.). 
Patient Groups 
Patients older than 18 years of age with an MoM or ceramic-on-ceramic (CoC) hip 
implant in situ for >12 months were recruited. They were divided into 3 age and sex-matched 
groups on the basis of prosthesis type and blood metal ion levels. Group A consisted of 
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patients with a CoC-bearing implant and normal whole-blood metal ion levels; Group B, 
patients with an MoM implant and low whole-blood metal ion levels (<7 ppb); and Group C, 
patients with an MoM implant and raised whole-blood metal ion levels (≥7 ppb). CoC was 
chosen over MoP couplings in Group A because of concerns regarding metal debris arising 
through trunnionosis in MoP implants, and 7 ppb was used as a cutoff point between Groups 
B and C as this represents the U.K. Medicines & Healthcare products Regulatory Agency 
(MHRA) recommended threshold above which there may be heightened concern6. 
Exclusion criteria were prior hip revision surgery, known atrial fibrillation or 
impaired renal function (estimated glomerular filtration rate of <30 mL/min), and standard 
contraindications to magnetic resonance imaging (MRI) (e.g., a pacemaker). Six patients—4 
of whom would have been assigned to group A (CoC) and 1 each of whom, to groups B and 
C—were excluded because of arrhythmias (e.g., atrial fibrillation). 
All participants gave written informed consent conforming to the Declaration of 
Helsinki (5th revision, 2000). All tests were performed at a single visit. Study data were 
collected and managed using REDCap (Research Electronic Data Capture software, version 
5.9.6, http://www.project-redcap.org/), with the cardiac investigators blinded to the study 
groups during data acquisition and analysis until study completion. 
Transthoracic Echocardiography 
Echocardiography was performed using a Vivid E9 ultrasound machine (GE 
Healthcare). Measurements were made according to the British Society of Echocardiography 
standard protocol26, including acquisition of standard 2-dimensional views, M-mode, spectral 
tissue Doppler imaging, and blood flow measurements (Fig. 2-A). 
CMR Acquisition 
Patients underwent CMR at 1.5 T (Avanto; Siemens Medical). Cardiac volumes and 
ejection fractions were calculated conventionally from short-axis cine images. 
Bright-blood T2* and precontrast T1 mapping of the myocardium and liver were 
acquired on a mid-left ventricular short axis slice and an axial mid-hepatic slice, respectively 
(Figs. 2-C and 2-D). As T1 mapping is not fully standardized, we used 2 implementations: 
modified look-locker (MOLLI) and shortened MOLLI (ShMOLLI) sequences (MyoMaps; 
Siemens). Late gadolinium-enhancement images were acquired using a motion-corrected 
phase sensitive inversion recovery sequence to identify focal myocardial fibrosis after 
administering 0.1 mmol/kg of gadolinium-based contrast medium (gadoterate meglumine 
[Dotarem; Guerbet]). Fifteen minutes after the injection of the contrast medium, T1 
sequences were repeated for extracellular volume quantification (Figs. 3-A, 3-B, and 3-C). 
Blood Biomarkers 
Blood sampling to measure B-type natriuretic peptide (BNP), troponin-I, and whole-
blood cobalt and chromium levels (Fig. 2-B) was performed before the patients underwent 
CMR. BNP and high-sensitivity troponin are the most commonly used biomarkers in 
cardiology. They cover a range of cardiac processes, with BNP measurements used to 
evaluate myocyte strain and troponin measurements indicating myocyte death. Both have 
prognostic importance. 
Whole-blood cobalt and chromium levels were measured using inductively coupled 
plasma mass spectrometry in the same U.K. reference laboratory to eliminate interlaboratory 
variation. 
Image Analysis 
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All image acquisition and analyses were performed by observers blinded to the study 
groups. Unblinding was performed by an independent statistician once all data had been 
acquired and analyzed, with the data set locked. 
Left ventricular volumes, ejection fraction, and mass were calculated from CMR data 
using standard techniques and dedicated software (CMRtools; Cardiovascular Imaging 
Solutions). Thresholding methods were used, and papillary muscles were considered part of 
the left ventricular myocardium. Volumes were subsequently indexed to body surface area. 
Two of the authors determined the presence of late gadolinium enhancement through visual 
assessment. 
For T2* and T1 measurements, a region of interest was manually drawn on the 
interventricular septum on each image, with care taken to avoid the endocardial and 
epicardial contours to minimize partial voluming effect. Extracellular volume was calculated 
using MOLLI sequences via a fully automated method that calculates pixel-wise extracellular 
volume parametric maps27, based on the standard formula: 
 
extracellular volume = (1 − hematocrit) × (ΔR1myocardium/ΔR1blood) 
 
where ΔR1 is the change in R1 from the postcontrast to the precontrast image, and R1 = 
1/T1. 
Echocardiographic data were digitally stored for offline analysis with EchoPAC 
dimension software (GE Healthcare). Conventional analysis of left ventricular structure and 
systolic and diastolic function including spectral tissue Doppler parameters were performed 
according to guidelines, with values averaged over 2 cardiac cycles. Tissue Doppler 
parameters for lateral and septal walls were averaged to produce a single marker of systolic 
longitudinal function. 
Study Size 
Sample size calculations were based on previously published data20, which indicated 
an absolute difference in ejection fraction of 5% (with a pooled standard deviation of 
approximately 8%) between patients with an MoM hip prosthesis and those with a 
conventional hip prosthesis. Using an alpha value of 0.05 and a 2:1 sample size ratio between 
MoM and CoC prostheses, we needed 62 patients with an MoM implant and 31 with a CoC 
implant to have a power of 80% to detect a 5% difference (Cohen delta = 0.63, classified as a 
medium to large effect). The MoM group was divided according to blood metal levels using 
7 ppb as a cutoff6 (yielding approximately a 1:1:1 ratio overall). 
Statistical Analysis 
The prespecified primary end points were ejection fraction (determined with CMR) 
and T2* measurement. The secondary end points included left ventricular end systolic 
volume index, T1, and extracellular volume measurements with CMR; ejection fraction and 
left atrial area index and left ventricular long axis function (mean of the lateral and septal S' 
velocities measured with echocardiography); and blood biomarkers. 
The 3 groups were assessed for matching using chi-square tests (or Fisher exact tests 
when the expected counts were <5) for binary variables and analysis of variance (ANOVA) 
for continuous variables. The distribution of the metal ions was not normal, and the group 
variances were highly heterogeneous; hence, nonparametric tests on medians were used to 
compare ion levels between groups. We used parametric and nonparametric test results to 
establish whether there was a significant difference in the mean and/or median effect on 
cardiac function between the groups. The distributions of the cardiac exposure variables in 
each group appeared normal for outcome variables of interest, with the variance usually 
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constant (according to the Bartlett test); thus, ANOVA (F test) was conducted for each 
marker. As the sample sizes were relatively small, a formal test for normality was not 
conducted. However, sensitivity analyses with nonparametric tests (comparing the median 
across groups) were performed to relax the parametric assumption, and they always 
confirmed the conclusions obtained for the mean (results not shown). The presence of 
significant results at a 5% significance level was further assessed by dividing the threshold by 
the number of tests conducted (Bonferroni correction). 
Correlations between whole-blood metal ion levels and ejection fraction and T2* 
values were calculated using the Pearson correlation coefficient (with metal ions log-
transformed) and Spearman correlation coefficient (with metal ions on the original scale). 
The minimum detectable effect size was calculated using Cohen’s d28. 
All calculations were performed using Stata 14 (StataCorp). 
Results 
Patients 
Ninety patients completed the study. Baseline patient characteristics are shown in 
Table I. Patients were matched for age and sex. Group A (CoC; n = 28) had a mean age (and 
standard deviation [SD]) of 65.3 ± 8.8 years, and 75% of the patients were female. Group B 
(MoM with a low metal-ion level; n = 33) had a mean age of 61.9 ± 11.9 years, and 64% 
were female. Group C (MoM with a high metal-ion level; n = 29) had a mean age of 67.6 ± 
10.8 years, and 62% were female. The mean cobalt levels in groups A, B, and C were 0.17 ± 
0.08, 2.47 ± 1.81, and 30.0 ± 29.1 ppb, respectively. 
The overall mean time from implantation of the prosthesis to the date of the scan was 
slightly shorter in group A than in group B or C (84 ± 33 versus 95 ± 22 and 107 ± 41 
months, F = 3.5, p = 0.03). 
Although the groups were not matched for body mass index (BMI), cardiovascular 
risk factors, or medications, there were no significant differences between them with regard 
to those factors. 
CMR 
The 3 groups did not differ significantly with regard to the mean left ventricular 
ejection fraction (70.1% ± 5.6%, 69.5% ± 6.8%, and 70.6% ± 5.5%, p = 0.75; Table II and 
Fig. 4) or the left ventricular end systolic volume index (p = 0.86). Additionally, we found no 
differences in the left ventricular ejection fraction or end systolic volume index when we 
combined groups B and C and compared the combined group with group A (Table II). 
The mean cardiac T2* values were normal in the 3 groups and did not differ 
significantly among them (p = 0.69) or between the combined MoM group (B and C) and 
group A (p = 0.85). All patients with high blood metal levels (Group C) had normal T2* 
values (>20 ms). The T1 values measured with both the MOLLI and the ShMOLLI 
techniques were normal in the 3 groups and did not differ significantly among the groups 
(MOLLI: p = 0.64; ShMOLLI: p = 0.82). The extracellular volume was normal in, and did 
not differ significantly among, the 3 groups (p = 0.28), with no outliers. 
The liver T2* values were normal in all patients. No differences were identified 
among the 3 groups (p = 0.67) or between the combined MoM group (B and C) and group A 
(p = 0.92). The liver T1 value and extracellular volume also did not differ significantly 
between or among groups (Table II). 
Transthoracic Echocardiography 
There was no significant difference in the left ventricular ejection fraction among 
groups A, B, and C (65% ± 6%, 62% ± 7%, and 63% ± 6%, respectively; p = 0.28). 
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Similarly, the left atrial volume index was similar among the 3 groups (p = 0.19) with no 
differences between the combined MoM group (B and C) and group A (p = 0.20). There were 
also no between-group differences in the mean lateral and septal S' velocities (p = 0.46). 
Blood Biomarkers 
There were no significant differences in the BNP level among groups A, B, and C 
(11.4, 10.8, and 24.9 pg/mL, respectively). Although the mean BNP level was highest in 
group C, the difference failed to reach significance (F = 1.17, p = 0.32). The troponin levels 
also did not differ significantly among the groups (p = 0.78). 
Electrocardiography (EKG) 
All study participants had a resting 12-lead EKG. In 5 participants (4 in group B and 1 
in group C), the EKG demonstrated left bundle branch block morphology (QRS duration of 
>120 ms). There were no ST or T-wave abnormalities, or changes reflecting previous cardiac 
events such as myocardial infarction. 
Metal Ions and Cardiac Function: Dose Response 
A dose-response linear correlation analysis was conducted using the Pearson 
coefficient to determine whether there was a relationship across groups between blood cobalt 
and chromium levels and left ventricular ejection fraction and T2* values. There was no 
significant linear correlation between the blood cobalt level (log scale) and the left ventricular 
ejection fraction (R = 0.022, 95% confidence interval [CI] = −0.185 to 0.229; p = 0.83) or the 
T2* value (R = 0.108, 95% CI = −0.105 to 0.312; p = 0.32). Similarly, no significant 
correlation was found between the blood chromium level and the left ventricular ejection 
fraction (R = 0.047, 95% CI = −0.162 to 0.251; p = 0.66) or the T2* value (R = 0.065, 95% 
CI = −0.148 to 0.272; p = 0.55) (Fig. 5). 
Whole-blood metal levels were non-normally distributed, unlike the left ventricular 
ejection fraction and the T2* value, and log-transforms attenuated without circumventing the 
lack of normality. Hence, to avoid this assumption, the Spearman correlation coefficient was 
also calculated, and it showed no significant correlation between the cobalt level and the left 
ventricular ejection fraction (rho = 0.038, 95% CI = −0.170 to 0.243; p = 0.72), between the 
cobalt level and the T2* value (rho = 0.074, 95% CI = −0.139 to 0.280; p = 0.50), between 
the chromium level and the left ventricular ejection fraction (rho = 0.058, 95% CI = −0.151 
to 0.262; p = 0.59), or between the chromium level and the T2* value (rho = 0.012, 95% CI = 
−0.200 to 0.222; p = 0.92). 
Discussion 
There is increasing concern regarding the effects of systemic cobalt and chromium 
toxicity in patients with MoM hip implants. Although the evidence for toxicity is limited, 
patient and surgeon anxiety is fueled by increasing numbers of case reports of end-organ 
damage and mortality10. In this study, we investigated the effects of metal ions on cardiac 
function in 3 distinct groups of patients defined by the type of hip implant and the level of 
circulating blood cobalt. Using 2 independent cardiac imaging techniques (including the gold 
standard, CMR), we failed to find a significant change in cardiac function in patients exposed 
to elevated metal ion levels. There was no significant correlation between elevated blood 
metal ion levels and cardiac function; even at the extremes of the 95% CI around the 
correlation coefficients, the correlations were negligible to weak. 
Our confidence in these results is based on the strengths of our study methodology, 
which included the use of both CMR and echocardiography as well as a meticulous trial 
design. We ensured a prespecified recruitment number, data acquisition in a dedicated 
cardiac imaging center separate from the recruiting center, and a cardiac care team 
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completely blinded to the study groups (during both acquisition and analysis) until the 
independent statistician returned the results. 
Tissue-mapping techniques also failed to identify any demonstrable metal deposition 
from circulating cobalt ions in the cardiac or liver tissues. Although we recently 
demonstrated25 that T2* mapping can detect biopsy-proven CoCr, the lack of demonstrable 
tissue deposition in the present study may be due to differences in the physical chemistry of 
cobalt ions compared with that of cobalt and chromium in combination. However, the fact 
that iron can be detected in the heart and liver using T2* mapping, and we previously 
detected CoCr (colocalized) in the liver25, indicates that the reason why the T2* findings 
were negative in all cases in the present study was either that the test is too insensitive or no 
deposition was occurring. T2* should be considered a candidate biomarker, which, if it had 
differed between the groups, would have indicated the biological process of deposition. The 
lack of functional consequences (demonstrated by complementary and independent imaging 
modalities [CMR and echocardiography] and 2 blood biomarkers) and the lack of positive 
T2* findings, although not definitive, are reassuring. 
A potential for cardiotoxicity from metal implants, as demonstrated by an inferior left 
ventricular ejection fraction, has been previously reported. However, these reports are limited 
to individual case reports and to studies with less rigorous methodology. For example, 
Prentice et al.20 used echocardiography, which has a higher interobserver variability than 
CMR, and that may account for the difference between their and our findings. We conclude 
that individual case reports of heart failure (mainly in patients with extreme ion levels) are 
not likely to be “the tip of the iceberg” or to indicate an unrecognized epidemic of occult 
MoM-related community heart failure. 
The pathophysiology behind a possible link between elevated blood cobalt levels and 
cardiac toxicity is unclear. Suggested theories include cobalt interference with cardiac 
myocyte oxygen uptake and transmembrane transport system disruption29. Histopathological 
findings in cobalt-related cardiac toxicity include myofibrillar hypertrophy, interstitial 
fibrosis, and muscle fiber degeneration30. However, calcified fibrils or other deposits within 
myofibrils are often absent, differentiating cobalt-induced cardiomyopathy from other 
etiologies13. It has been postulated that cobalt-related cardiac toxicity is due to additional 
predisposing factors, including poor nutrition and excessive alcohol intake as was seen in the 
Quebec beer-drinkers cobalt cardiomyopathy epidemic (in which foam stabilizer contained 
10 times the usual quantity of cobalt)30. Recent case reports of cardiac toxicity in association 
with MoM hip implants mainly involved patients with extremely elevated blood cobalt levels 
(>100 ppb). Because of current national surveillance programs, such patients are now likely 
to have undergone revision surgery, with presumed reduction in their risk of systemic 
toxicity. 
We believe that these findings offer reassurance to surgeons and will help them 
counsel the >1 million patients worldwide with MoM hip implants. Additional work is 
needed, particularly from large-volume linkage studies currently under way internationally. 
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Fig. 1 
Flow diagram of the study methods. ECHO = echocardiogram, LV = left ventricular, EF = 
ejection fraction, ESVi = end systolic volume index, ECV = extracellular volume, LAVi = left 
atrial volume index, BNB = B-type natriuretic peptide, and Trop I = troponin I. 
Fig. 2 
Comprehensive cardiac assessment included transthoracic echocardiography (Fig. 2-A), 
measurement of blood biomarker levels (BNP and troponin I) (Fig. 2-B), CMR (Fig. 2-C), 
and scar imaging (Fig. 2-D). 
Fig. 3 
Precontrast (Fig. 3-A) and postcontrast (Fig. 3-B) T1 mapping combined for extracellular 
volume mapping (Fig. 3-C). 
Fig. 4 
Scatterplot demonstrating the mean left ventricular ejection fraction (LVEF), and the SD, for 
the 3 groups. 
Fig. 5 
Correlation plots with line of best fit. Whole-blood cobalt and chromium levels are compared 
with the left ventricular ejection fraction (LVEF; top row) and T2* values (bottom row). 
Pearson correlation coefficients (R values) are provided for each. 
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TABLE I Patient Demographics by Study Group 
Demographic All Patients Group A Group B Group C P Value 
Sample (no.) 90 28 33 29  
Age* (yr) 64.9 ± 10.5 65.3 ± 8.80 61.9 ± 11.9 67.6 ± 10.8 0.115 
Sex (F/M) (no.) 60/30 21/7 21/12 18/11 0.525 
Time since implantation* 
(yr) 
8.76 ± 2.34 7.86 ± 2.62 9.03 ± 1.87 9.39 ± 2.52 0.041 
BMI† (kg/m2) 28 28 (18-38) 28 (20-45) 27 (20-48) 0.929 
Diabetes (no.; %) 3; 3 1; 4 1; 3 1; 3 0.982 
Hypertension (no.; %) 32; 36 11; 39 12; 36 9; 31 0.715 
Hypercholesterolemia 
(no.; %) 
20; 22 9; 32 4; 12 7; 24 0.105 
Medications (no.; %)      
β blocker 5; 8 2; 7 0 3; 10 0.181 
ACE inhibiter‡ 10; 11 5; 18 3; 9 2; 7 0.326 
Thiazide diuretic 8; 9 2; 7 4; 12 2; 7 0.741 
Calcium channel 
blocker 
15; 17 7; 25 4; 12 4; 14 0.289 
Aspirin 3; 3 1; 4 0 2; 7 0.317 
Statin 20; 22 9; 32 4; 12 7; 24 0.121 
Proton pump inhibitor 18; 20 8; 29 3; 9 7; 24 0.101 
Thyroxine 8; 9 4; 14 4; 12 0 0.108 
Hemoglobin level† (g/dL) 14 14.1 14.2 13.6 0.134 
Cobalt level† (ppb) 10.9 0.17 (0.10-
0.47) 
2.47 (0.73-
6.97) 
30.01 (7.54-
118) 
<0.0001 
Chromium level† (ppb) 7.7 0.74 (0.53-
1.42) 
2.84 (0.94-
10.5) 
19.6 (1.71-
69.0) 
<0.0001 
*The values are given as the mean and SD. †The values are given as the mean with or without the range in parentheses. 
‡ACE = angiotensin-converting-enzyme.  
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TABLE II CMR, Echocardiographic, and Blood Biomarker Results 
    P Value 
Measurement† 
Group A (N = 
28)* 
Group B (N 
= 33)* 
Group C (N 
= 29)* 
A vs. B vs. 
C 
A vs. B and 
C 
CMR      
Left ventricular 
ejection fraction (%) 
70 ± 5 69 ± 7 71 ± 5 0.75 0.96 
End systolic volume 
index (mL/m2) 
21 ± 6 21 ± 8 20 ± 5 0.86 0.99 
T1 MOLLI: heart (NR = 
949-1101 ms) (ms) 
1,030 ± 42 1,014 ± 33 1,022 ± 37 0.64 0.15 
T1 ShMOLLI: heart 
(NR = 900-1,020 ms) 
(ms) 
961 ± 31 957 ± 30 956 ± 44 0.82 0.54 
T2*: heart (normal = 
>20 ms) (ms) 
31 ± 5 31 ± 6 32 ± 6 0.69 0.85 
Extracellular volume: 
heart 
0.28 ± 0.03 0.27 ± 0.03 0.29 ± 0.04 0.28 0.62 
T1 mapping: liver (ms) 616 ± 72 596 ± 78 584 ± 49 0.21 0.11 
T2* mapping: liver 
(normal = >6.3 ms) 
(ms) 
25 ± 4 26 ± 7 25 ± 5 0.67 0.92 
Extracellular volume: 
liver 
0.29 ± 0.04 0.30 ± 0.03 0.30 ± 0.04 0.62 0.36 
 Echocardiography           
Left ventricular end 
diastolic diameter 
(mm) 
43 ± 9 45 ± 5 45 ± 6 0.26 0.10 
Left ventricular end 
systolic diameter 
(mm) 
28 ± 6 30 ± 4 30 ± 5 0.18 0.06 
Left ventricular 
ejection fraction (%) 
65 ± 6 62 ± 7 63 ± 6 0.28 0.12 
Left ventricular lateral 
wall tissue Doppler 
imaging (m/s) 
0.09 ± 0.02 0.08 ± 0.02 0.09 ± 0.02 0.24 0.16 
Left ventricular septal 
wall tissue Doppler 
imaging (m/s) 
0.08 ± 0.02 0.07 ± 0.02 0.08 ± 0.01 0.16 0.12 
Left atrial volume 
index (mL/m2) 
27 ± 6 28 ± 7 31 ± 8 0.19 0.20 
Blood biomarker 
sampling 
          
BNP (normal = <47 
pmol/L) (pmol/L) 
11 ± 10 10 ± 8 25 ± 61 0.32 0.52 
Troponin (NR = 0-14 
ng/L) (ng/L) 
7.38 ± 6.9 7.16 ± 5.0 8.62 ± 10.2 0.77 0.78 
*Data are presented as the mean and SD. †NR = normal range. 
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